All In Biotech

Drug Trial Radar · NCT05452239

A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of add-on Eptinezumab Treatment to Brief Educational Intervention for the Preventive Treatment of Migraine in Patients With Dual Diagnosis of Migraine and Medication Overuse Headache

Last checked: Nov 20, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 608 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

608

Actual

Start

Jul 1, 2022

Primary completion

Oct 22, 2024

Study completion Mar 13, 2025

Sponsor

Lead sponsor
H. Lundbeck A/SIndustry
Sponsor type
Industry
First posted
Jul 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins). Treatment of MOH usually involves reducing the dose of or discontinuing acute medications. Eptinezumab is a medication used for the preventive treatment of migraine in adults. The main goals of this trial are to learn whether eptinezumab helps reduce the number of days with migraine, the number of days with headache, and acute medication use in adults who have migraine and MOH.

Conditions

  • Migraine
  • Medication Overuse Headache

Interventions

  • EptinezumabDrug

    Solution for infusion

  • PlaceboDrug

    Solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Placebo-controlled Period: Change From Baseline in the Number of MMDs at Weeks 1 - 4Time frame: Baseline, Weeks 1 - 4

Locations

76 sites in 11 countries. Site status is shown where the registry gives one.

  • Clinical Research of Central Florida - ClinEdge - PPDS

    Winter Haven, Florida

  • Legacy Clinical Solutions: Tandem Clinical Research LLC - Medical Center - Marrero - ClinEdge - PPDS

    Marrero, Louisiana

  • Clinvest - National Ave - Headlands - PPDS

    Springfield, Missouri

  • Dent Neurologic Institute - Amherst

    Amherst, New York

  • Headache Center - Montefiore Medical Center - BRANY - PPDS

    The Bronx, New York

  • Texas Center for Drug Development, Inc

    Houston, Texas

  • Southern Neurology

    Kogarah, New South Wales, Australia

  • Mater Adult Hospital

    South Brisbane, Queensland, Australia

  • Austin Hospital

    Heidelberg, Victoria, Australia

  • Alfred Health

    Melbourne, Victoria, Australia

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • Sydvestjysk Sygehus Esbjerg

    Esbjerg, Denmark

  • Danish Headache Center

    Glostrup Municipality, Capital, Denmark

  • AP-HP - Hopital Lariboisiere

    Paris, France

  • Groupe Hospitalier Paris Saint Joseph

    Paris, France

  • CHU de Nice

    Nice, Alpes-Maritimes, France

  • Assistance Publique Hopitaux de Marseille

    Marseille, Bouches-du-Rhône, France

  • Hôpital Pierre-Paul Riquet

    Toulouse, Haute-Garonne, France

  • Centre Hospitalier Annecy Genevois - Site d'Annecy

    Pringy, Haute-Savoie, France

  • CHRU Nantes

    Saint-Herblain, Loire-Atlantique, France

  • Hôpital Roger Salengro

    Lille, Nord, France

  • Centre Hospitalier Universitaire de Saint Etienne

    Saint-Priest-en-Jarez, Pays de la Loire Region, France

  • Centre Hospitalier Universitaire de Clermont Ferrand -58 Rue Montalembert

    Clermont-Ferrand, Puy-de-Dôme, France

  • Hospices Civils de Lyon - Hôpital Pierre Wertheimer

    Bron, Rhône, France

  • Malkhaz Katsiashvili Multiprofile Emergency Medicine Center-Gobronidze 10

    Tbilisi, Georgia

  • Ltd Israel-Georgia Medical Research Clinic Helsicore

    Tbilisi, Georgia

  • Pineo Medical Ecosystem

    Tbilisi, Georgia

  • Aversi Clinic LTD

    Tbilisi, Georgia

  • MediClubGeorgia Ltd

    Tbilisi, Georgia

  • S. Khechinashvili University Clinic, Ltd.

    Tbilisi, Georgia

  • Multiprofile Clinic Consilium Medulla

    Tbilisi, Georgia

  • Universitätsmedizin Greifswald

    Greifswald, Germany

  • Klinikverbund Südwest - Kliniken Sindelfingen

    Sindelfingen, Baden-Wurttemberg, Germany

  • Kopfschmerzzentrum Frankfurt

    Frankfurt am Main, Hesse, Germany

  • Studienzentrum Nord-West

    Westerstede, Lower Saxony, Germany

  • Praxis fuer Neurologie, Spezielle Schmerztherapie und Psychotherapie

    Essen, North Rhine-Westphalia, Germany

  • Universitätsklinikum Essen

    Essen, North Rhine-Westphalia, Germany

  • Universitätsklinikum Carl Gustav Carus an der TU Dresden

    Dresden, Saxony, Germany

  • Universitatsklinikum Jena - Am Klinikum 1-Erlanger Allee 101

    Jena, Thuringia, Germany

  • Azienda Ospedaliero Universitaria Di Modena Policlinico

    Modena, Italy

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.